Summary edit edit source
Small Pharma Inc., a biotechnology company, focuses on developing short-acting psychedelics with therapy for the treatment of mental health conditions. The company's clinical program is N,N-dimethyltryptamine assisted therapy to treat major depressive disorder. It is also developing a pipeline of proprietary preclinical assets. The company was founded in 2015 and is headquartered in London, the United Kingdom.